Clinical trial NCT04406480: Realization of Sequencing of All Known Human Genes in Case of Detection of Cerebral, Renal or Ophthalmological Fetal Malformations During Pregnancy in Order to Make an Etiological Diagnosis and to Precise the Fetal Prognosis
Official title: Contribution of the Exome Sequencing in Antenatal Period Behind Ultrasound Features Suggestive of a Rare Genetic Disease
Study type: INTERVENTIONAL
Overall status: UNKNOWN
Phase: NA
Conditions: Fetal Malformation
Pregnancy Related
Rare Genetic Disease
Keywords: Fetal malformations
Exome sequencing
antenatal cerebral malformations
antenatal ocular malformations
antenatal large hyperechoic kidneys
Lead sponsor: University Hospital, Strasbourg, France
Sponsor class: OTHER
First posted: 2020-05-28
Enrollment: 90
Sex: ALL
Minimum age (years): 18
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Allocation: NA
Intervention model: SINGLE_GROUP
Primary purpose: DIAGNOSTIC

Brief summary: Congenital malformations concern 3% of pregnancies; most of them can be seen during pregnancy. For some malformations, an invasive sample (trophoblast biopsy or amniocentesis) is proposed to search a chromosomal abnormality by the technique of DNA chip. However, some strongly suggestive signs of a genetic (and not chromosomal) pathology have a very low diagnostic rate with this technique. In the absence of an etiological diagnosis, the prognosis for the unborn child is very difficult to assess, as we can't know if the fetal malformation is really isolated or associted to other unseen features as part of a syndromic condition.

For some malformations strongly suggestive of a genetic condition, we propose to realize an exome (i.e. all coding parts of the genome) sequencing of the trio (child and the 2 parents) with a delivery time compatible with the emergency situation of a pregnancy (6 weeks maximum). We will apply bioinformatics filters to analyse only genes known to be involved in the malformation present in the unborn child and thus avoid the identification of variants in unrelated genes. These lists of genes have been previously validated by the Rare Disease Health Sectors and the affiliated diagnostic laboratories. The selected malformations are: 1) anomalies of the central nervous system (microcephaly (\<- 2DS) with anomalies of gyration, anomalies of the posterior fossa, anomalies of the midline except agenesis of the corpus callosum), 2) ophthalmological anomalies (microphthalmia, hyperplasia vitreous) and 3) renal abnormalities (large hyperechoic kidneys).


Eligibility criteria: Inclusion Criteria:

* Father and mother of an unborn child past the age of majority
* Consent dated and signed by the mother and by the father
* Father and mother able to understand the objectives and risks of the study
* For the mother, pregnancy in progress (between 12 and 34 weeks)
* For the mother, pregnancy with the presence of a malformation on ultrasound, confirmed by a doctor from the multidisciplinary diagnostic prenatal center, entering into the indications retained for this study
* Clinical validation of the couple's eligibility by an expert for some of selected indications
* Father and mother affiliated to a social protection health

Exclusion Criteria:

* Identified genetic or chromosomal abnormality explaining the observed malformation
* Inability to give informations to the father and / or mother (father or mother in emergency or life-threatening situation)
* Father and / or mother under the protection of justice
* Father and / or mother under guardianship or curatorship
* Nursing woman

Primary outcomes:
measure: Diagnostic contribution of the exome sequencing in antenatal period in comparison with the chromosomal analysis (CGH-array) realized in current health care
timeFrame: 13 months
Secondary outcomes:
measure: Effects on pregnancy management and/or postnatal child care due to an etiological diagnosis
timeFrame: 13 months
measure: Feasibility study of carrying out exome sequencing in the antenatal period in terms of time to deliver results
timeFrame: 13 months
Other outcomes:
measure: Difficulties of interpretation of the exome sequencing in antenatal period
timeFrame: 13 months
measure: Identification of new genes responsible of fetal malformations
timeFrame: 13 months
Locations:
city: Besançon
country: France
facility: CHu de Besançon
city: Dijon
country: France
facility: CHU de Dijon
city: Lyon
country: France
facility: Hospices Civils de Lyon
city: Mulhouse
country: France
facility: Groupe Hospitalier Region Mulhouse Et Sud Alsace
city: Nancy
country: France
facility: CHU de Nancy
city: Paris
country: France
facility: Hôpital d'Enfants Armand-Trousseau
city: Paris
country: France
facility: Hôpital de la Pitié Salpêtrière
city: Paris
country: France
facility: Hôpital Necker Enfants Malades
city: Reims
country: France
facility: CHU de Reims
city: Rennes
country: France
facility: CHU de Rennes
city: Strasbourg
country: France
facility: Les Hôpitaux Universitaires de Strasbourg
city: Toulouse
country: France
facility: CHU de Toulouse
Study officials:
References: